Keyword: South Korea

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

The Zantac recall is quickly turning into a landslide as CVS pulled Zantac and its generics as did countries from Korea to Bangladesh.

South Korea’s JW Pharmaceutical has started targeting emerging markets with a deal for a plant in Vietnam.

South Korea's SK Holdings is rolling three API operations into a new unit, SK Pharmteco, and has put its headquarters in Sacramento, California.

Original Takeda employees alleged faced unfair changes in their roles and got different incentive plans during the integration.

Samsung Bioepis wins FDA nod for a Humira biosim; Celltrion forms Chinese biosim joint venture; GenScript debuts a clinical biologics plant.

Roche, Daiichi and AZ nab global first nods from Japan; Celgene hands back PD-1 to BeiGene; China offers incentive to generic makers.

Hansoh and Hengrui chiefs together make one of biopharma's richest families; prosecutors grill top Samsung exec; FDA cites another Aurobindo plant.

Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.

Samsung BioLogics has faced scrutiny of a biosimilars joint venture. Now, officials are looking more closely into the company's 2016 public listing.